Pfizer made the decision amid the success of its COVID-19 vaccine that was developed with German company BioNTech. However, Pfizer plans to produce new vaccines without a partnership.
The new technology differs from how traditional vaccines have worked. Traditional vaccines contained dead viruses that initiated an antibody response from the immune systems. mRNA technology allows drugmakers to copy the genetic make of a virus and copy it without actually putting the virus into the vaccine.
Pfizer Chief Executive Officer Albert Bourla believes the company is ready to pursue mRNA as a solo operation after its experience with the COVID-19 vaccine.